Sibel Health Respiratory Sensor Accepted Into FDA Drug Development Tool Program

According to a recent LinkedIn post from Sibel Health, the company’s Aria cough monitoring sensor has been accepted into the FDA Drug Development Tool Clinical Outcome Assessment Qualification Program. The post suggests this represents the third such acceptance for Sibel Health and emphasizes growing interest in continuous, automated, and clinically meaningful respiratory measurements to support drug development.

The LinkedIn post highlights that the Aria sensor is designed to provide real-time, objective cough detection without capturing identifiable audio, aiming to reduce burden for patients and researchers while addressing privacy concerns. For investors, inclusion in the FDA DDT COA program may enhance Sibel Health’s credibility with pharmaceutical partners and clinical trial sponsors, potentially expanding its role in respiratory drug development and supporting long-term commercialization prospects in digital health and wearable clinical trial tools.